Any investigative reporter will tell you that a case dismissal does not necessarily mean a victory. Here's how that rule of thumb figures into the case of Dan Markingson, who committed suicide after participating in a clinical trial for the psychiatric drug Seroquel.
A candid email from a university publicist sheds some, but not enough, light on why the university won't provide documents from a controversial Seroquel clinical study.
It can be uncomfortable asking people about their finances. In journalism, though, there is an obligation not only to ask, but to ask for proof — especially with clinical trials.
One of the biggest oversights a health writer can make is to cover a scientific study and not talk about its funders. William Heisel examines what can happen when a study's funding is overlooked.
Bioethicist and writer Carl Elliott used many documents to piece together the story of how a research team desperate for patients helped create a pipeline for clinical trial participants by setting up a psychiatric ward. Here's how he did it.
Documents behind a controversial Seroquel drug trial raise serious questions about how patients with mental disorders are judged competent to participate in clinical trials all over the world.
A war of words has erupted at the University of Minnesota campus over bioethics writer and UM professor Carl Elliott’s reporting into the suicide of a schizophrenic patient enrolled in a clinical trial.
Dr. Carl Elliott, a University of Minnesota bioethicist, has spent much of the last two years doggedly pursuing the case of Dan Markingson, a 26-year-old who killed himself during a UM clinical trial meant to prove the superiority of AstraZeneca’s Seroquel over its competitors.